06:00 PM EDT, 09/15/2025 (MT Newswires) -- MDxHealth ( MDXH ) said late Monday it closed its acquisition of Exosome Diagnostics, including the ExoDx Prostate test, a CLIA-certified lab, and related assets from Bio-Techne ( TECH ) .

The $15 million deal includes $5 million in stock at closing and $2.5 million annually over four years, with 50% in cash and 50% in cash or stock at MDxHealth's ( MDXH ) discretion, the company said.